Article preview from Medtech Insight - August 2013

Neovasc Inc. is targeting two highly underserved markets in cardiology – refractory angina and mitral valve disease – with unique transcatheter solutions. The angina device, called the Neovasc Reducer, is expected to enter the European market early next year.

Article preview from Start-Up - December, 2012

Transcutaneous electrical nerve stimulation technology has been used for decades to noninvasively treat acute and chronic pain in the muscles, joints, back, and neck. Now, InControl Medical LLC is employing it in the form of an intravaginal probe combined with patient biofeedback and quantitative physician feedback to treat one of the largest and fastest growing female health care problems, stress and mixed urinary incontinence.

InControl Medical LLC

Article preview from Start-Up - December, 2012

Transcutaneous electrical nerve stimulation (TENS) technology has been used for nearly 40 years to noninvasively and with low risk treat acute and chronic pain in the muscles, joints, back, and neck. Among other indications, it has also been used to stimulate the pelvic floor muscles to treat urinary problems such as overactive bladder and various forms of incontinence. And now, this strategy is being employed in the form of an intravaginal probe combined with patient biofeedback and quantitative physician feedback to treat one of the largest and fastest growing female health care problems, stress and mixed urinary incontinence. Wisconsin-based start-up InControl Medical LLC launched itsInTone electronic nerve stimulation device in mid-2012, and the company says its sales are growing rapidly.

The company is led by Hershel "Buzz" Peddicord, who has had a 35-year career in the medical device industry. He served in executive roles at cardiac pacemaker company Biotronik and patient monitoring company Criticare Systems Inc., before founding HomMed LLC, a provider of home health telemonitoring equipment, in 1999. HomMed did well in just a five-year time span, and it was acquired by the Fortune 100 company Honeywell International Inc. in 2004 for $128 million. In 2005, Peddicord was looking for his next entrepreneurial opportunity, and his mother gave him the idea for developing a non-surgical device to help the millions of women who suffer from urinary incontinence. The InTone electronic nerve stimulation device was developed and designed in 2008 by Peddicord and a team of engineers, based on the principle that poor muscle tone in the pelvic floor muscles caused by childbirth, trauma, lack of exercise, and other factors is most often the root cause of incontinence. Once Peddicord had developed a workable prototype via the engineers and suppliers in the Midwest, he secured a round of funding from undisclosed angel investors and launched InControl Medical in August 2010. He also brought aboard some key team members from his previous company, HomMed.

Continued…

To read this article in its entirety, purchase now as a PDF and receive it immediately via email. Or get it FREE when you subscribe to Start-Up.

About Start-Up

No publication reviews leading edge companies and technology better than Start-Up. Each issue of Start-Up profiles the most important new product companies, identifies the hottest technology areas, reviews funds flowing into private companies and investment trends, and reports on university tech transfer licensing. Industries covered: pharmaceuticals, biotechnology, medical equipment & devices, and in vitro diagnostics.

Plus:
To find out about more about more about Elsevier Business Intelligence’s medical device publications and databases, multi-user access and/or advertising with Medical Devices Today, please contact Kristy Kennedy at (480) 985-9512

Article preview from The Gray Sheet- November 7, 2013

Medtronic appeared to have the edge over Atlanta Scientific in Nov. 5 oral arguments over which side needs to prove its case when a patent licensee sues its licensor to get out of paying product royalties. The Supreme Court ruling has implications for which side has more leverage in licensing agreements, which are common in the device industry.

Article preview from Dr. Cole - May 2014

Groundbreaking new laser liposuction technologies could shift the future direction of Plastic Surgery and Medical markets. New innovative technologies will allow patients to suffer less inconveniences and side-effects. The progress achieved in medical devices dedicated to plastic surgery like Liposuction, have created a cloud of better plastic surgery services for most patients, and also have expanded the opportunities to new patients. Costs have also been decreased, which translates into less fees charged to the patient.

to read more on Laser technologies like Vanquish visit Dr. Cole’s Atlanta liposuction website.

Article preview from IN VIVO - September, 2013

Amir Belson is among the most prolific device entrepreneurs in the industry today, having launched a dozen companies in the past 12 years. Not as well-known as other physician-inventors, he combines an aggressive IP strategy with an innovative approach to early-stage financing to launch companies in a variety of clinical spaces.

Article preview from "The Gray Sheet"- November 4, 2013

Companies have recently started to launch implants constructed via 3-D printing to increase product customization and to save on costs. FDA says the additive manufacturing techniques are a promising form of personalized medicine.

Article preview from IN VIVO - December, 2012

Baxter’s offer of $4 billion for Swedish hemodialysis manufacturer Gambro may be one of the largest medtech acquisitions of the year, but Baxter CEO Bob Parkinson describes the deal as a bolt-on for Baxter’s existing market in renal therapy. Of course the magnitude of the deal makes it “an adjacency with a capital A”, Parkinson quipped.

Baxter Acquires Gambro, Becomes Integrated Renal Therapy Leader

Article preview from IN VIVO - December, 2012

Baxter International Inc.’s offer of $4 billion for Swedish hemodialysis manufacturer Gambro AB may be one of the largest medtech acquisitions of the year. Baxter CEO Bob Parkinson describes the deal as a bolt-on for an existing product space and well within Baxter’s announced strategy of growing its existing clinical markets. Of course the magnitude of the deal makes it “an adjacency with a capital A” Parkinson quipped in a conference call on December 4.

The dialysis industry has several segments divided between chronic and acute renal failure. The product segments include equipment for in-center hemodialysis, hospital-based dialysis, peritoneal dialysis, and an emerging market in home dialysis. Dialysis (the extracorporeal cleansing of the blood of patients with dysfunctional kidneys) is also a service industry and the leading equipment manufacturer in the space, Fresenius Medical Care AG (a division of Fresenius SE & Co. KGAA) also owns and operates dialysis centers.

Baxter is a leader in peritoneal dialysis (a home-based therapy that uses the membrane of the peritoneal cavity and dialysis solutions to cleanse the blood of toxins) with 72% of the market, and also offers equipment for home hemodialysis. Gambro is a leader in hemodialysis products for both the chronic and acute-care segments of the market. With the acquisition, Baxter thus gains a new breadth and scale in renal therapy. It transforms itself from a leader in one segment with 2011 sales of $2.5 billion into a new, larger, and diversified competitor with pro forma renal therapy sales of $4.2 billion. The deal values Gambro at a multiple of 14x (enterprise value/EBITDA) while Baxter and the rest of the sector trade at 8x.